Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$44.72 (-5.13%) as of
Key statistics
- Market cap
- 296.82B
- P/E (TTM)
- 34.40
- Forward P/E
- 26.65
- EPS (TTM)
- 1.300
- Dividend yield
- 0.42%
- 52-week range
- 43.020 – 80.950
- Beta
- 0.04
- Revenue (TTM)
- 32.56B
- Profit margin
- 24.93%
- Analyst target
- HK$78.92
- Volume
- 4.84M
About Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Lianyungang, China
- Employees
- 20,602
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.